Nephrolyx offers a precise and rapid measurement of the kidney function (true GFR). We provide hospitals and laboratories with an In-Vitro Diagnostic Test and a digital platform to measure the true GFR within only a few hours. For the first time, physicians can detect renal diseases using the highest accuracy of GFR measurement and adapt an optimal treatment plan for patients. Especially nephrology, oncology, transplantation, and ICU patients can benefit from rapid and precise diagnostics. The Nephrolyx IVDx is indicated for the in-vitro quantitative determination of serum iohexol concentration and calculation of the glomerular filtration rate (GFR). The principle of the test is based on Ultra-High-Performance-Liquid Chromatography using Ultra-Violet light. Proprietary technology from Nephrolyx helps to improve treatment success for kidney patients. Given its low component cost, the Nephrolyx IVDx can also significantly enhance the performance of the entire healthcare system.
| Website | http://nephrolyx.com/ |
| Employees | 10 (6 on RocketReach) |
| Founded | 2021 |
| Address | Johann-Hittorf Straße 8, Berlin, Berlin 12489, DE |
| Industry | Biotechnology Research |
| Keywords | Kidney Disease Management, Clinical Diagnostics, Laboratory Diagnostics, Kidney Health, Point-Of-Care Diagnostics, Hospital Diagnostics, Medical Diagnostics, Digital Health Platform |
| Competitors | CVS Health, DaVita Kidney Care, Fresenius Medical Care, Baxter International Inc., アステラス製薬(株), American Dialysis Ctr, Dialyze Direct, Rockwell Medical, Inc., NantKwest, Keryx Biopharmaceuticals +43 more (view full list) |
Looking for a particular Nephrolyx employee's phone or email?
Markus Riester is the CEO of Nephrolyx.
6 people are employed at Nephrolyx.
Nephrolyx is based in Berlin, Berlin.